Please ensure Javascript is enabled for purposes of website accessibility

FDA Allows States to Approve Their Own Coronavirus Tests

By Prosper Junior Bakiny - Updated Mar 24, 2020 at 2:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This should accelerate the process of getting more people tested for COVID-19.

The COVID-19 pandemic continues to march across the United States. There are now more than 4,600 confirmed cases in this country, and  85 people here have died from it, according to the Johns Hopkins University Coronavirus Resource Center. State and local governments are taking intensive measures to help mitigate the spread of the SARS-CoV-2 virus that causes the disease, such as closing public schools, gyms, bars and restaurants, and banning large gatherings. 

Federal agencies also taking steps. The Food and Drug Administration recently announced it would allow states to approve COVID-19 tests. The FDA would typically have to review such tests for approval, but considering the current crisis, the regulator is giving states the authority to grant the green light to tests developed in laboratories within their territories. This should help significantly speed up the approval process for such tests. 

Woman on the phone wearing a mask

Image Source: Getty Images.

Testing is critical in the fight against COVID-19

That wasn't the first time in this crisis that the FDA has relaxed its usual procedures for the sake of expediency. Last week, the health industry regulator issued an emergency use authorization for Roche's (RHHBY -1.05%) test to detect the SARS-CoV-2 virus; the pharma company says it will have "millions of tests a month available." The FDA's emergency use authorization was granted faster and with less data than the agency requires for its standard review and approval process. Hopefully, these measures to  address the relative scarcity of COVID-19 tests in the U.S. will allow doctors and epidemiologists to ramp up diagnoses, as identifying those who have contracted the disease is essential to inhibiting its spread. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.57 (-1.05%) $0.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.